#USA #New York #Class Action #Pomerantz Law Firm #REGENXBIO

Pomerantz Law Firm Takes Action on Behalf of REGENXBIO Investors

On February 19, 2026, Pomerantz LLP announced a significant development for investors of REGENXBIO Inc. (NASDAQ: RGNX). The firm has initiated a class action lawsuit following allegations of securities fraud and other unlawful business practices by the company’s executives. Investors who experienced losses are encouraged to take action, and they have until April 14, 2026, to apply for the position of Lead Plaintiff in this case.

Background of the Case

The serious allegations against REGENXBIO stem from a press release issued on January 28, 2026. The release highlighted that the U.S. Food and Drug Administration (FDA) had blocked the company's investigational gene therapies, RGX-111 and RGX-121, pending further evaluation due to potential cancer risks observed in clinical trials. Specifically, one trial participant developed a CNS tumor, leading the FDA to pause the studies on both therapies due to comparable risks associated with their patient demographic.

In response to this news, REGENXBIO's stock plummeted by $2.40, resulting in a drastic 17.9% decrease and closing at $11.01 per share. This sharp decline has sparked concern among investors and prompted the filing of the class action lawsuit.

How to Get Involved

Investors who purchased REGENXBIO securities during the relevant period and sustained losses are urged to reach out to Pomerantz LLP's Danielle Peyton at [email protected] or via phone at 646-581-9980 (or toll-free at 888-4-POMLAW, Ext. 7980). Interested parties should provide their mailing address, phone number, and the number of shares they acquired when contacting the firm for further action. A copy of the complaint can also be accessed through Pomerantz’s website for those seeking detailed information about the case.

Pomerantz LLP: A Leader in Class Action Litigation

With over 85 years of experience, Pomerantz LLP is renowned in the realm of corporate, securities, and antitrust litigation. Founded by the distinguished Abraham L. Pomerantz, who played a pivotal role in advancing class action law, the firm has consistently championed the rights of investors against corporate malfeasance. Their history is marked by successful multimillion-dollar recoveries for class members affected by securities fraud and breaches of fiduciary duties.

The firm’s commitment to transparency and advocacy makes it a trusted choice for individuals navigating complex legal challenges following substantial financial losses. As the landscape of corporate governance continues to evolve, Pomerantz remains steadfast in its mission to protect investors' rights.

In conclusion, those affected by potential misconduct at REGENXBIO Inc. are encouraged to consider their options and may find recourse through this class action. Time is of the essence as the April deadline approaches, making immediate action crucial for impacted investors to assert their rights and seek compensation.